靶向成纤维细胞激活蛋白的FAPI PET/MRI在乳腺癌中的应用
该回顾性研究评估了68Ga-FAPI-46 PET/MRI在19例浸润性乳腺癌患者中对原发灶及分期的价值。结果显示所有18例未治疗原发灶及13例术前证实的淋巴结转移均呈高摄取,7例检出腋外淋巴结受累,3例影响了治疗决策。
要点
- 68Ga-FAPI-46 PET/MRI对原发乳腺癌及淋巴结转移显示强摄取,有助于清晰勾勒肿瘤。
- FAPI PET可检出腋外淋巴结受累,可能影响分期和治疗决策。
- 研究为回顾性小样本,FAPI在乳腺癌的诊断价值需进一步验证。
关键影像表现/征象
- 所有18例未治疗原发乳腺恶性肿瘤均显示强示踪剂摄取,平均SUVmax为13.9(范围7.9-29.9),中位病灶直径26 mm(范围9-155 mm)。
- 不同分级、受体状态和组织学类型的肿瘤均能清晰 delineation。
- 13例女性中所有术前证实的淋巴结转移均显示强摄取,平均SUVmax为12.2(范围3.3-22.4),平均直径21 mm(范围14-35 mm)。
临床应用与阅片要点
- FAPI PET/MRI可用于原发乳腺癌病灶的评估,强摄取有助于肿瘤 delineation。
- 全身FAPI扫描可评估淋巴结及远处分期,检出腋外淋巴结受累可能影响治疗决策。
局限性
- 回顾性分析,样本量小(19例),单中心。
- 结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Integrated PET/MRI is a promising modality for breast assessment. The most frequently used tracer, fluorine 18 (18F) fluorodeoxyglucose (FDG), is applied for whole-body staging in advanced breast cancer but has limited accuracy in evaluating primary breast lesions. The fibroblast-activation protein (FAP) is abundantly expressed in invasive breast cancer. FAP-directed PET tracers have recently become available, but results in primary breast tumors remain lacking. Purpose To evaluate the use of FAP inhibitor (FAPI) breast PET/MRI in assessing breast lesions and of FAPI whole-body scanning for lymph node (LN) and distant staging using the ligand gallium 68 (68Ga)-FAPI-46. Materials and Methods In women with histologically confirmed invasive breast cancer, all primary 68Ga-FAPI-46 breast and whole-body PET/MRI and PET/CT examinations conducted at the authors' center between October 2019 and December 2020 were retrospectively analyzed. MRI lesion characteristics and standardized uptake values (SUVs) were quantified with dedicated software. Mann-Whitney U tests were used to compare tumor SUVs across different tumor types. The Pearson correlation coefficient was calculated between SUV and measures of MRI morphologic characteristics. Results Nineteen women (mean age, 49 years ± 9 [standard deviation]) were evaluated-18 to complement initial staging and one for restaging after therapy for distant metastases. Strong tracer accumulation was observed in all 18 untreated primary breast malignancies (mean maximum SUV [SUVmax] = 13.9 [range, 7.9-29.9]; median lesion diameter = 26 mm [range, 9-155 mm]), resulting in clear tumor delineation across different gradings, receptors, and histologic types. All preoperatively verified LN metastases in 13 women showed strong tracer accumulation (mean SUVmax= 12.2 [range, 3.3-22.4]; mean diameter = 21 mm [range, 14-35 mm]). Tracer uptake established or supported extra-axillary LN involvement in seven women and affected therapy decisions in three women. Conclusion This retrospective analysis indicates use of 68Ga fibroblast-activation protein inhibitor tracers for breast cancer diagnosis and staging. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Mankoff and Sellmyer in this issue.
引用
- Backhaus P, Burg MC, Roll W, et al. Simultaneous FAPI PET/MRI Targeting the Fibroblast-Activation Protein for Breast Cancer. Radiology. 2021. PMID: 34636633. doi:10.1148/radiol.2021204677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。